Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 2/20 | 0.48 |
| ▸ | TSHR | P16473 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | MMP9 | P14780 | 1/20 | 0.48 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL575402 | 0.82 | ALDH1A1 (0.48) | USP2TSHRALDH1A1KDM4ELMNA | |
| SCHEMBL19024347 | 0.82 | ALDH1A1 (0.48) | USP2TSHRALDH1A1KDM4ELMNA | |
| SCHEMBL13369382 | 0.80 | ALDH1A1 (0.46) | USP2TSHRALDH1A1KDM4ELMNA | |
| SCHEMBL1205705 | 0.79 | USP2 (0.50) | USP2TSHRALDH1A1KDM4ELMNA | |
| SCHEMBL3706344 | 0.78 | ALDH1A1 (0.55) | USP2TSHRALDH1A1KDM4ELMNA | |
| SCHEMBL7618433 | 0.78 | USP2 (0.55) | USP2TSHRALDH1A1KDM4ELMNA | |
| SCHEMBL2166721 | 0.77 | ALDH1A1 (0.43) | USP2TSHRALDH1A1KDM4ELMNA | |
| SCHEMBL13858563 | 0.76 | USP2 (0.40) | USP2TSHRALDH1A1KDM4ELMNA | |
| SCHEMBL13858561 | 0.76 | USP2 (0.40) | USP2TSHRALDH1A1KDM4ELMNA | |
| SCHEMBL27038345 | 0.76 | USP2 (0.40) | USP2TSHRALDH1A1KDM4ELMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8530504-B2 | Pyrazolothiazole compound | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2013-09-10 | — | — | US | disclosed |
| US-8530504-B2 | Pyrazolothiazole compound | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2013-09-10 | — | — | US | disclosed |
| US-8530504-B2 | Pyrazolothiazole compound | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2013-09-10 | — | — | US | disclosed |
| US-8293146-B2 | Optical film and phase difference plate, and liquid crystal compound | FUJIFILM CORPORATION (JP) | 2012-10-23 | — | — | US | disclosed |
| EP-2487178-A1 | PYRAZOLOTHIAZOLE COMPOUND | Eisai R&D Management Co., Ltd. (JP) | 2012-08-15 | — | — | EP | disclosed |
| EP-2487178-A1 | PYRAZOLOTHIAZOLE COMPOUND | Eisai R&D Management Co., Ltd. (JP) | 2012-08-15 | — | — | EP | disclosed |
| US-20110086882-A1 | PYRAZOLOTHIAZOLE COMPOUND | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2011-04-14 | — | — | US | disclosed |
| US-20110086882-A1 | PYRAZOLOTHIAZOLE COMPOUND | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2011-04-14 | — | — | US | disclosed |
| US-20110086882-A1 | PYRAZOLOTHIAZOLE COMPOUND | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2011-04-14 | — | — | US | disclosed |
| US-20090159857-A1 | OPTICAL FILM AND PHASE DIFFERENCE PLATE, AND LIQUID CRYSTAL COMPOUND | FUJIFILM CORPORATION (JP) | 2009-06-25 | — | — | US | disclosed |
| WO-2007091716-A1 | OPTICAL FILM AND PHASE DIFFERENCE PLATE, AND LIQUID CRYSTAL COMPOUND | FUJIFILM CORPORATION (JP) | 2007-08-16 | — | — | WO | disclosed |
| US-20060079533-A1 | Methods of treating alzheimer's disease | NIEMAN JAMES A | 2006-04-13 | — | — | US | disclosed |
| US-6969712-B2 | Benzimidazole derivatives | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2005-11-29 | — | — | US | disclosed |
| US-20050261331-A1 | Substituted pyrrolopyridines | ASTRAZENECA AB (SE) | 2005-11-24 | — | — | US | disclosed |
| US-20040044056-A1 | Benzimidazole derivatives | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2004-03-04 | — | — | US | disclosed |
| EP-1342717-A1 | BENZIMIDAZOLE DERIVATIVES | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2003-09-10 | — | — | EP | disclosed |
| WO-2002076440-A2 | METHODS OF TREATING ALZHEIMER'S DISEASE WITH PIPERIDIN DERIVATES | ELAN PHARMACEUTICALS, INC. (US) | 2002-10-03 | — | — | WO | disclosed |
| US-6150526-A | Piperidine derivative having renin inhibiting activity | HOFFMANN-LA ROCHE INC. (US) | 2000-11-21 | — | — | US | disclosed |
| US-6051712-A | PREVENTION OF HIGH BLOOD PRESSURE AND CARDIAC INSUFFICIENCY, AS WELL AS GLAUCOMA, CARDIAC INFARCT, KIDNEY INSUFFICIENCY AND RESTENOSIS | HOFFMANN-LA ROCHE INC. (US) | 2000-04-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090159857-A1 | OPTICAL FILM AND PHASE DIFFERENCE PLATE, AND LIQUID CRYSTAL COMPOUND | NOM1, CRYZ, CNN2 | USP2 2106/4885TSHR 4352/4885ALDH1A1 4388/4885 |
| US-20110086882-A1 | PYRAZOLOTHIAZOLE COMPOUND | CRHR1, CNR1, AGTR1 | USP2 4349/4885TSHR 132/4885ALDH1A1 1527/4885 |
| US-20050261331-A1 | Substituted pyrrolopyridines | ITK, WEE1, PDPK1 | USP2 4219/4885TSHR 1467/4885ALDH1A1 1591/4885 |
| US-20060079533-A1 | Methods of treating alzheimer's disease | BACE1, PSEN1, PSEN2 | USP2 1490/4885TSHR 3417/4885ALDH1A1 2504/4885 |
| US-20040044056-A1 | Benzimidazole derivatives | GPR119, OPRL1, INSR | USP2 4219/4885TSHR 239/4885ALDH1A1 1851/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.